| Objective:To explore the clinical effect of lung cancer ? prescription in patients with advanced lung squamous cell carcinoma and to provide evidence for its application.We confirm the efficacy of Chinese medicine as well as verify its safety,so as to avoid the risk of clinical application.Methods:A randomized controlled design was used in this study.Patients with primary lung squamous cell carcinoma who were first treated in Shanxi Tumor Hospital from March2015 to October 2016 were screened by the inclusion and exclusion criteria and 68 cases of subjects enrolled in the study.These subjects were randomly assigned to control group(34 cases:GP regimen chemotherapy only)and experimental group(34 cases:GP regimen chemotherapy and Lung cancer ? prescription)with 2 cycles of chemotherapy(21 day regimen)as the observation window.The changes of tumor and the score of TCM syndromes,the quality of life and the indexes of immunology in the two groups were recorded before and after treatment.The bone marrow suppression and gastrointestinal toxicity were recorded and the safety of the drugs was evaluated.SPSS20.0 software was used for statistical analysis.Results:1.Baseline characteristics: This clinical observation included a total of 68 eligible subjects,the comparison of the clinical data between the two groups in gender,age,TNM stage,KPS score,TCM syndrome score,P>0.05,there was no significant difference between the two groups and comparability exists.2.Effect Evaluation: After the observation the objective evaluation of tumor in western medicine,the effective rate of the experimental group(44.1%)was slightly higher than that of the control group(38.2%),2c=0.243,P>0.05,there was no significant difference.However the TCM Syndrome Evaluation in two groups,the effective rate of the experimental group(47.1%)was significantly higher than that of the control group(23.5%),2c=4.121,P<0.05,the two groups have significant differences.3.Life quality and immune function: Compared with the KPS score,the effective rate of the experimental group was 38.2% and that of the control group was14.7%,2c=4.836,P=0.028<0.05,showed a statistically significant difference.Immunological indexes of the two groups' subjects in the initial test of CD4+ cells and the ratio of CD4+/CD8+ were lower than normal,the difference between groups was not significant,comparability exists.After 2 cycles of treatment,CD4+/CD8+ratio and NK cell count decreased while CD8+ cells increased,but there was no significant difference in the control group.CD4+ cells in the experimental group were higher while CD8+ cells were lower,but there was no difference between two groups,the ratio of CD4+/CD8+increased after treatment,compared within the experimental group,t=-2.397,P<0.05,the difference was statistically significant.The ratio of CD4+/CD8+ compared between two groups after treatment,t=2.197,P<0.05,there were significant differences.4.Side effects: In two groups of white blood cells,neutrophils,platelets and reduce anemia has not significant differences(P?0.05);nausea and vomiting occurred during chemotherapy,constipation and other gastrointestinal reactions.The experimental group in reducing chemotherapy gastrointestinal discomfort has more advantages,p<0.05,the difference was statistically significant.5.In the observation period,there were no serious adverse events in the two groups.Conclusion:Lung cancer II prescription combined with chemotherapy can reduce the burden of advanced LSCC patients with Yin deficiency symptoms,improve the quality of life,enhance immune function and significantly reduce gastrointestinal adverse reactions such as nausea and vomiting,constipation.Clinical application is safe and reliable. |
PDF Full Text Request